ReviewVirulence2023
An important call: Suggestion of using IL-10 as therapeutic agent for COVID-19 with ARDS and other complications.
Review in Virulence, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 36 citations in OpenAlex.
- Nebulized glycyrrhizin/enoxolone drug modulates IL-17A in COVID-19 patients: a randomized clinical trial.Frontiers in immunology · 2023Trial
- Liquid Lung Rest During Extracorporeal Life Support in a Neonatal Porcine Model of Acute Lung Injury.ASAIO journal (American Society for Artificial Internal Organs : 1992) · 2026Article
- The Framework of Host Innate and Adaptive Immunological Pathways.Biomedicines · 2026Review
- Attenuating pulmonary injury and inflammation with C5/CD14 inhibition therapy: results from a porcine polytrauma model with blunt chest trauma.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2026Article
- Interleukins in COVID-19 and SARS-CoV-2 Variants: Immunopathogenesis, Therapeutic Perspectives and Vaccine-Induced Immune Responses.International journal of molecular sciences · 2026Review
- Article
- Identification of Integrated Stress Response-Related Biomarkers in Sepsis-Induced Acute Respiratory Distress Syndrome.Mediators of inflammation · 2026Article
- Mechanisms of Interleukin-10-Mediated Immunosuppression in Viral Infections.Pathogens (Basel, Switzerland) · 2025Review
- Interleukin-10 family cytokines: key regulators and novel therapeutic targets for respiratory diseases.Inflammopharmacology · 2025Review
- Limiting endosomal damage sensing reduces inflammation triggered by lipid nanoparticle endosomal escape.Nature nanotechnology · 2025Article
- Elevated IL-6 and IL-10 Levels as Prognostic Biomarkers in COVID-19 Pneumonia: A Comparative Study in Mexican Patients.Healthcare (Basel, Switzerland) · 2025Article
- The Complex Immune Cell Composition and Cellular Interaction in the Alveolar Compartment of Patients with Acute Respiratory Distress Syndrome.American journal of respiratory cell and molecular biology · 2025Review
- ARDS severity in COVID-19: a case-control study of laboratory biomarkers and IL-10 SNP analysis.Upsala journal of medical sciences · 2025Article
- Ocular neuroinflammatory response secondary to SARS-CoV-2 infection-a review.Frontiers in immunology · 2025Review
- Advances in interleukin-10-based therapies for pulmonary diseases: focus on targeted lung delivery systems.Frontiers in immunology · 2025Review
- Experimental animal models of acute respiratory distress syndrome: one-hit and two-hit establishment application.Frontiers in immunology · 2025Review
- Review
- Review
- Progress in cytokine research for ARDS: A comprehensive review.Open medicine (Warsaw, Poland) · 2024Review
- Tracking inflammation resolution signatures in lungs after SARS-CoV-2 omicron BA.1 infection of K18-hACE2 mice.PloS one · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global coronavirus disease 2019 (COVID-19) pandemic has a detrimental impact on public health. COVID-19 usually manifests as pneumonia, which can progress into acute respiratory distress syndrome (ARDS) related to uncontrolled TH17 immune reaction. Currently, there is no effective therapeutic agent to manage COVID-19 with complications. The currently available anti-viral drug remdesivir has an effectiveness of 30% in SARS-CoV-2-induced severe complications. Thus, there is a need to identify effective agents to treat COVID-19 and the associated acute lung injury and other complications. The host immunological pathway against this virus typically involves the THαβ immune response. THαβ immunity is triggered by type 1 interferon and interleukin-27 (IL-27), and the main effector cells of the THαβ immune response are IL10-CD4 T cells, CD8 T cells, NK cells, and IgG1-producing B cells. In particular, IL-10 exerts a potent immunomodulatory or anti-inflammatory effect and is an anti-fibrotic agent for pulmonary fibrosis. Concurrently, IL-10 can ameliorate acute lung injury or ARDS, especially those caused by viruses. Owing to its anti-viral activity and anti-pro-inflammatory effects, in this review, IL-10 is suggested as a possible treatment agent for COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.